Abstract CT053: Exploration of potential biomarkers correlated with efficacy of ociperlimab (anti-TIGIT) plus tislelizumab (anti-PD-1) in 1L PD-L1+ non-small cell lung cancer (NSCLC)
Authors: Kim Se Hyun , Zhang Jiayuan , Tan Wei , Yan Han , Tian Tian , Zheng Hao , Zhou Ziqi , Wang Ruihua , Zhang Yun , Shen Zhirong , Kim Hye Ryun , Zhong Diansheng , Lu Shun 
Published: April 2024

Abstract
Background: PD-L1 expression was associated with anti-immunoglobulin and immunoreceptor tyrosine-based inhibitory motif domains (TIGIT) + anti-PD-(L)1 treatment, in which a high PD-L1 subgroup showed improved efficacy. We investigated if anti-TIGIT mechanism of action (MOA)-related markers were associated with the efficacy of ociperlimab + tislelizumab in Cohort 3 (1L PD-L1+ NSCLC) of the phase 1/1b AdvanTIG-105 trial (NCT04047862) and evaluated a potential patient-enrichment strategy based on tumor tissue gene expression profile (GEP).
Methods: Tumor tissue GEP was tested using TruSeq RNA Access technology. Ventana SP263 PD-L1 immunohistochemistry (IHC) assay was used to evaluate PD-L1 expression. Median progression-free survival (mPFS) by investigator was calculated descriptively by Kaplan-Meier methodology. 95% confidence intervals for mPFS were generated using the Brookmeyer method. The primary inferential PFS comparison used unstratified log-rank test with 2-sided descriptive P-values.
Results: At data cutoff (Feb 2, 2023), 24 of 45 patients had GEP results. Anti-TIGIT MOA-related genes and signatures correlated with ociperlimab + tislelizumab treatment response. Patients with high (H) vs low (L) expression of TIGIT, CD226, CCR8, or a tumor-associated macrophage (TAM) signature had significantly longer mPFS (Table). Dual biomarkers combining both anti-PD-L1 (PD-L1 IHC) and one of the anti-TIGIT MOA-related factors (TIGIT, CCR8, TAM signature GEP) identified subgroups of PD-L1 H + TIGIT MOA-related factor H patients with improved PFS vs other subgroups (Table). A highly overlapped PD-L1 H + TIGIT H + CCR8 H + TAM signature H patient population was observed in dual biomarker analyses.
Conclusions: Anti-TIGIT MOA-related genes and signatures correlated with efficacy in ociperlimab + tislelizumab-treated 1L PD-L1+ NSCLC. Combining anti-TIGIT MOA-related factors with PD-L1 expression identified a subgroup of patients with improved efficacy.

TABLE 1. NAND Table. Efficacy Analyses in Patient Subgroups TIGITa CD226b CCR8b TAMb Subgroup H L H L H L H L n 8 16 12 12 12 12 12 12 mPFS, months (95% CI) NR (2.6, NR) 5.26 (2.07, 11.86) NR (4.21, NR) 4.68 (1.41, 15.05) 15.21 (2.6, NR) 4.7 (1.71, 7.16) 15.21 (4.21, NR) 4.17 (1.71, 5.45) PFS, P-value 0.0326 0.0327 0.0131 0.0153 PD-L1c + TIGITb PD-L1c + CCR8b PD-L1c + TAMb Subgroup TIGITHPD-L1H TIGITHPD-L1L TIGITLPD-L1H TIGITL PD-L1L CCR8HPD-L1H CCR8HPD-L1L CCR8LPD-L1H CCR8L PD-L1L TAMHPD-L1H TAMHPD-L1L TAMLPD-L1H TAML PD-L1L n 8 4 8 4 11 1 5 7 9 3 7 5 mPFS, months (95% CI) NR (1.41,NR) 4.76 (2.6,NR) 8.62 (2.07,NR) 2.94 (1.25,NR) NR (1.41,NR) 2.6 (NR,NR) 5.19 (2.07,NR) 4.21 (1.25,7.16) 23.89 (1.41,NR) 5.32 (4.21,NR) 5.29 (2.07,NR) 2.6 (1.25,NR) Cutoff: aTop 1/3; bMedian; cTC≥25%
Citation Format: Se Hyun Kim, Jiayuan Zhang, Wei Tan, Han Yan, Tian Tian, Hao Zheng, Ziqi Zhou, Ruihua Wang, Yun Zhang, Zhirong Shen, Hye Ryun Kim, Diansheng Zhong, Shun Lu. Exploration of potential biomarkers correlated with efficacy of ociperlimab (anti-TIGIT) plus tislelizumab (anti-PD-1) in 1L PD-L1+ non-small cell lung cancer (NSCLC) [abstract]. In: Proceedings of the American Association for Cancer Research Annual Meeting 2024; Part 2 (Late-Breaking, Clinical Trial, and Invited Abstracts); 2024 Apr 5-10; San Diego, CA. Philadelphia (PA): AACR; Cancer Res 2024;84(7_Suppl):Abstract nr CT053.